Aminoglycoside antibiotics cochleotoxicity in paediatric cystic fibrosis (CF) patients: A study using extended high-frequency audiometry and distortion product otoacoustic emissions

References

• American Speech-Language-Hearing Association. 1994. American Speech-Language-Hearing Association: Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy. ASHA 36 (suppl. 12), 11–19.
   Google Scholar
• Aran J.M. 1995. Current perspectives on inner ear toxicity. Otolaryngol Head Neck Surg, 112, 1, 133–144.
   PubMed Web of Science ®Google Scholar
• Arnold D.J., Lonsbury-Martin B.L., Martin G.K. 1999. High-frequency hearing influences lower-frequency distortion-product otoacoustic emissions. Arch Otolaryngol Head Neck Surg, 125, 2, 215–222.
   PubMedGoogle Scholar
• Bailey T.C., Little J.R., Littenberg B., Reichley R.M., Dunagan W.C. 1997. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis, 24, 5, 786–795.
   PubMed Web of Science ®Google Scholar
• Barclay M.L., Begg E.J., Chambers S.T., Thornley P.E., Pattemore P.K. . 1996. Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis. J Antimicrob Chemother, 37, 6, 1155–1164.
   PubMed Web of Science ®Google Scholar
• Barza M., Ioannidis J.P., Cappelleri J.C., Lau J. 1996. Single or multiple daily doses of aminoglycosides: A meta-analysis. BMJ, 312, 7027, 338–345.
   PubMed Web of Science ®Google Scholar
• Begg E.J., Barclay M.L. 1995. Aminoglycosides: 50 years on. Br J Clin Pharmacology, 39, 6, 597–603.
   PubMed Web of Science ®Google Scholar
• Brummett I.E. 1980. Drug-induced ototoxicity. Drugs, 19, 6, 412–428.
   PubMed Web of Science ®Google Scholar
• BASE. 1992. Recommended procedure for tympanometry. British Society of Audiology Br J Audiol, 26, 4, 255–257.
   PubMedGoogle Scholar
• Campbell K. 2003. Ototoxicity: Understanding oxidative mechanisms. J Am Acad Audiol, 14, 3, 121–123.
   PubMedGoogle Scholar
• Campbell K.C., Meech R.P., Klemens J.J., Gerberi M.T., Dyrstad S.S. . 2007. Prevention of noise- and drug-induced hearing loss with D-methionine. Hear Res, 226, 1–2, 92–103.
   PubMed Web of Science ®Google Scholar
• Cheng A.G., Johnston P.R., Luz J., Uluer A., Fligor B. . 2009. Sensorineural hearing loss in patients with cystic fibrosis. Otolaryngol Head Neck Surg. 141, 1, 86–90.
   PubMed Web of Science ®Google Scholar
• Chen Y., Huang W.G., Zha D.J., Qiu J.H., Wang J.L. . 2007. Aspirin attenuates gentamicin ototoxicity: From the laboratory to the clinic. Hear Res, 226, 1–2, 78–182.
   Web of Science ®Google Scholar
• Cone L.A. 1982. A survey of prospective, controlled clinical trials of gentamicin, tobramycin, amikacin, and netilmicin. Clin Ther, 5, 2, 155–162.
   PubMed Web of Science ®Google Scholar
• Conrad D.J., Stenbit A.E., Zettner E.M., Wick I., Eckhardt C. . 2008. Frequency of mitochondrial 12S ribosomal RNA variants in an adult cystic fibrosis population. Pharmacogenet Genomics, 8, 12, 1095–1102.
   Google Scholar
• Conway S.P., Miller M.G., Ramsden C., Littlewood J.M. 1985. Intensive treatment of pseudomonas chest infection in cystic fibrosis: A comparison of tobramycin and ticarcillin, and netilmicin and ticarcillin. Acta Paediatr Scand, 74, 1, 107–113.
   PubMed Web of Science ®Google Scholar
• Crifo S., Antonelli M., Gagliardi M., Lucarelli N., Marcolini P. 1980. Ototoxicity of aminoglucoside antibiotics in long-term treatment for cystic fibrosis. Int J Pediatr Otorhinolaryngol, 2, 3, 251–253.
   PubMed Web of Science ®Google Scholar
• Fausti S.A., Larson V.D., Noffsinger D., Wilson R., Phillips D.S. . 1994. High-frequency audiometric monitoring strategies for early detection of ototoxicity. Ear Hear, 15, 3, 232–239.
   PubMed Web of Science ®Google Scholar
• Fausti S.A., Rappaport B.Z., Schechter M.A., Frey R.H., Ward T.T. . 1984. Detection of aminoglycoside ototoxicity by high-frequency auditory evaluation: Selected case studies. Am J Otolaryngol, 5, 3, 177–182.
   PubMed Web of Science ®Google Scholar
• Fetoni A.R., Sergi B., Ferraresi A., Paludetti G., Troiani D. 2004. alpha-Tocopherol protective effects on gentamicin ototoxicity: An experimental study. Int J Audiol, 43, 3, 166–171.
   PubMed Web of Science ®Google Scholar
• Fischel-Ghodsian N., Prezant T.R., Chaltraw W.E., Wendt K.A., Nelson R. . 1997. Mitochondrial gene mutation is a significant predisposing factor in aminoglycoside ototoxicity. Am J Otolaryngol, 18, 3, 173–178.
   PubMed Web of Science ®Google Scholar
• Forge A., Schacht J. 2000. Aminoglycoside antibiotics. Audiol Neurootol, 5, 1, 3–22.
   PubMed Web of Science ®Google Scholar
• Fox K.E., Brummett R.E., Brown R., Himes D. 1980. A comparative study of the ototoxicity of gentamicin and gentamicin C1. Arch Otolaryngol, 106, 1, 44–49.
   PubMedGoogle Scholar
• Frank T. 2001. High-frequency (8 to 16 kHz) reference thresholds and intrasubject threshold variability relative to ototoxicity criteria using a Sennheiser HDA 200 earphone. Ear Hear, 22, 2, 161–168.
   PubMed Web of Science ®Google Scholar
• Friend P.A. 1986. Pulmonary infection in cystic fibrosis. J Infect, 13, 1, 55–72.
   PubMed Web of Science ®Google Scholar
• Gallo-Teran J., Arellano B., Morales-Angulo C., Modamio-Hoybjor S., Moreno-Pelayo M.A. . 2004. Prevalence of the A1555G mutation in the mitochondrial DNA in patients with cochlear or vestibular damage due to aminoglycoside-induced ototoxicity. Acta Otorrinolaringol Esp, 55, 5, 212–217.
   PubMedGoogle Scholar
• Govaerts P.J., Claes J., van de Heyning P.H., Jorens P.G., Marquet J., De Broe M.E. 1990. Aminoglycoside-induced ototoxicity, Toxicol Lett, 52, 3, 227–251.
   PubMed Web of Science ®Google Scholar
• Groh D., Pelanova J., Jilek M., Popelar J., Kabelka Z. . 2006. Changes in otoacoustic emissions and high-frequency hearing thresholds in children and adolescents. Hear Res, 212, 1–2, 90–98.
   PubMed Web of Science ®Google Scholar
• Guan M.X., Fischel-Ghodsian N., Attardi G. 2000. A biochemical basis for the inherited susceptibility to aminoglycoside ototoxicity. Hum Mol Genet, 9, 12, 1787–1793.
   PubMed Web of Science ®Google Scholar
• Gurtler N., Schmuziger N., Kim Y., Mhatre A.N., Jungi M., Lalwani A.K. 2005. Audiologic testing and molecular analysis of 12S rRNA in patients receiving aminoglycosides, Laryngoscope, 115, 4, 640–644.
   PubMed Web of Science ®Google Scholar
• Haughton P.M. 1995. Audiometer calibration: applying the earphone to the coupler, Br J Audiol, 29, 3, 188–191.
   PubMed Web of Science ®Google Scholar
• Hobbie S.N., Akshay S., Kalapala S.K., Bruell C.M., Shcherbakov D. . 2008. Genetic analysis of interactions with eukaryotic rRNA identify the mitoribosome as target in aminoglycoside ototoxicity. Proc Natl Acad Sci USA, 105, 52, 20888–20893.
   PubMed Web of Science ®Google Scholar
• Jacob L.C., Aguiar F.P., Tomiasi A.A., Tschoeke S.N., Bitencourt R.F. 2006. Auditory monitoring in ototoxicity, Braz J Otorhinolaryngol, 72, 6, 836–844.
   PubMedGoogle Scholar
• Kahlmeter G., Dahlager J.I. 1984. Aminoglycoside toxicity: A review of clinical studies published between 1975 and 1982. J Antimicrob Chemother, 13, Suppl. A, 9–22.
   PubMed Web of Science ®Google Scholar
• Katbamna B., Homnick D.N., Marks J.H. 1998. Contralateral suppression of distortion product otoacoustic emissions in children with cystic fibrosis: Effects of tobramycin. J Am Acad Audiol, 9, 3, 172–178.
   PubMedGoogle Scholar
• Knight K.R., Kraemer D.F., Neuwelt E.A. 2005. Ototoxicity in children receiving platinum chemotherapy: Underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol, 23, 34, 8588–8596.
   PubMed Web of Science ®Google Scholar
• Knight K.R., Kraemer D.F., Winter C., Neuwelt E.A. 2007. Early changes in auditory function as a result of platinum chemotherapy: Use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol, 25, 10, 1190–1195.
   PubMed Web of Science ®Google Scholar
• Lightfoot G.R. 2000. Audiometer calibration: interpreting and applying the standards. Br J Audiol, 34, 5, 311–316.
   PubMed Web of Science ®Google Scholar
• Littman T.A., Magruder A., Strother D.R. 1998. Monitoring and predicting ototoxic damage using distortion-product otoacoustic emissions: Pediatric case study. J Am Acad Audiol, 9, 4, 257–262.
   PubMedGoogle Scholar
• Lonsbury-Martin B.L., Martin G.K. 2001. Evoked otoacoustic emissions as objective screeners for ototoxicity. Sem Hear, 22, 377–391.
   Google Scholar
• Lutman M.E., Davis A.C. 1994, The distribution of hearing threshold levels in the general population aged 18–30 years. Audiology, 33, 6, 327–350.
   PubMedGoogle Scholar
• Mulheran M., Degg C. 1997. Comparison of distortion product OAE generation between a patient group requiring frequent gentamicin therapy and control subjects. Br J Audiol, 31, 1, 5–9.
   PubMed Web of Science ®Google Scholar
• Mulheran M., Degg C., Burr S., Morgan D.W., Stableforth D.E. 2001. Occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated high-dose aminoglycoside therapy. Antimicrobial Agents & Chemotherapy, 45, 9, 2502–2509.
   PubMed Web of Science ®Google Scholar
• Mulherin D., Fahy J., Grant W., Keogan M., Kavanagh B., FitzGerald M. 1991. Aminoglycoside induced ototoxicity in patients with cystic fibrosis. Irish Journal of Medical Science, 160, 6, 173–175.
   PubMed Web of Science ®Google Scholar
• Pedersen S.S., Jensen T., Osterhammel D., Osterhammel P. 1987. Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis. Antimicrobial Agents and Chemotherapy, 31, 4, 594–599.
   PubMed Web of Science ®Google Scholar
• Prezant T.R., Chaltraw W.E. Jr., Fischel-Ghodsian N. 1996. Identification of an overexpressed yeast gene which prevents aminoglycoside toxicity. Microbiology, 142, 12, 3407–3414.
   PubMedGoogle Scholar
• Rasmussen A.N., Osterhammel P.A., Lund S.P., Kristiansen G.B., Andersen S. 2005. A system for measuring distortion product otoacoustic emissions at ultra-sonic frequencies in rodents. Int J Audiol, 44, 4, 237–243.
   PubMed Web of Science ®Google Scholar
• Reavis K.M., Phillips D.S., Fausti S.A., Gordon J.S., Helt W.J. . 2008. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss. Ear Hear, 29, 6, 875–893.
   PubMed Web of Science ®Google Scholar
• Ress B.D., Sridhar K.S., Balkany T.J., Waxman G.M., Stagner B.B. . 1999, Effects of cis-platinum chemotherapy on otoacoustic emissions: The development of an objective screening protocol. Third place: Resident Clinical Science Award 1998, Otolaryngol Head Neck Surg, 121, 6, 693–701.
   PubMed Web of Science ®Google Scholar
• Riethmueller J., Ballmann M., Schroeter T.W., Franke P., von Butler R. and German Multicenter Study Group. 2009. Tobramycin once- vs. thrice-daily for elective intravenous antipseudomonal therapy in pediatric cystic fibrosis patients. Infection, 37, 5, 424–431.
   PubMed Web of Science ®Google Scholar
• Sataloff J., Wagner S., Menduke H. 1964. Kanamycin ototoxicity in healthy men. Arch Otolaryngol, 80, 413–417.
   PubMedGoogle Scholar
• Selimoglu E. 2007. Aminoglycoside-induced ototoxicity. Curr Pharm Des, 13, 1, 119–126.
   PubMed Web of Science ®Google Scholar
• Sha S.H., Qiu J.H., Schacht J. 2006. Aspirin to prevent gentamicin-induced hearing loss. N Engl J Med, 354, 17, 1856–1857.
   PubMed Web of Science ®Google Scholar
• Sha S.H., Schacht J. 2000. Antioxidants attenuate gentamicin-induced free radical formation in vitro and ototoxicity in vivo: D-methionine is a potential protectant. Hear Res, 142, 1–2, 34–40.
   PubMed Web of Science ®Google Scholar
• Sinswat P., Wu W.J., Sha S.H., Schacht J. 2000. Protection from ototoxicity of intraperitoneal gentamicin in guinea pig. Kidney Int, 58, 6, 2525–2532.
   PubMed Web of Science ®Google Scholar
• Smith P.A., Foster J.R. 1997. Audiometer calibration: Two neglected areas. Br J Audiol, 31, 5, 359–364.
   PubMed Web of Science ®Google Scholar
• Smyth A.R., Tan K.H. 2006. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.[update of Cochrane Database Syst Rev. 2000;(4):CD002009; PMID: 11034740]. [Review] [29 refs]. Cochrane Database of Systematic Reviews, 3, CD002009.
   Google Scholar
• Stavroulaki P., Vossinakis I.C., Dinopoulou D., Doudounakis S., Adamopoulos G. . 2002, Otoacoustic emissions for monitoring aminoglycoside-induced ototoxicity in children with cystic fibrosis. Arch Otolaryngol Head Neck Surg, 128, 2, 150–155.
   PubMed Web of Science ®Google Scholar
• Szaff M., Hoiby N., Flensborg E.W. 1983. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand, 72, 5, 651–657.
   PubMed Web of Science ®Google Scholar
• Tan K.H., Mulheran M., Knox A.J., Smyth A.R. 2003. Aminoglycoside prescribing and surveillance in cystic fibrosis. [Review] [47 refs]. American Journal of Respiratory & Critical Care Medicine, 167, 6, 819–823.
   PubMed Web of Science ®Google Scholar
• Van Meter D.J., Corriveau M., Ahern J.W., Lahiri T. 2009. A survey of once-daily dosage tobramycin therapy in patients with cystic fibrosis. Pediatric Pulmonology, 44, 4, 325–329.
   PubMed Web of Science ®Google Scholar
• Vold+Öich L. 1965. The kinetics of streptomycin, kanamycin and neomycin in the inner ear. Acta Oto-Laryngologica, 60, 1, 243–248.
   PubMedGoogle Scholar
• Waterson J.A., Halmagyi G.M. 1998. Unilateral vestibulotoxicity due to systemic gentamicin therapy. Acta Otolaryngol (Stockh), 118, 474–478.
   PubMed Web of Science ®Google Scholar
• Wood P.J., Ioannides-Demos L.L., Li S.C., Williams T.J., Hickey B. . 1996. Minimisation of aminoglycoside toxicity in patients with cystic fibrosis”, Thorax, 51, 4, 369–373.
   PubMed Web of Science ®Google Scholar
• Wright G.D., Berghuis A.M., Mobashery S. 1998. Aminoglycoside antibiotics. structures, functions, and resistance. Adv Exp Med Biol, 456, 27–69.
   PubMed Web of Science ®Google Scholar